Free Trial

Anixa Biosciences (ANIX) Stock Price, News & Analysis

-0.07 (-2.46%)
(As of 01:56 PM ET)
Today's Range
50-Day Range
52-Week Range
93,292 shs
Average Volume
131,288 shs
Market Capitalization
$88.36 million
P/E Ratio
Dividend Yield
Price Target

Anixa Biosciences MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
333.2% Upside
$12.00 Price Target
Short Interest
2.08% of Float Sold Short
Dividend Strength
News Sentiment
1.27mentions of Anixa Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$182,130 Bought Last Quarter
Proj. Earnings Growth
From ($0.44) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.58 out of 5 stars

Medical Sector

460th out of 918 stocks

Pharmaceutical Preparations Industry

209th out of 421 stocks

ANIX stock logo

About Anixa Biosciences Stock (NASDAQ:ANIX)

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

ANIX Stock Price History

ANIX Stock News Headlines

Anixa Biosciences (NASDAQ:ANIX) Trading Down 1%
ANIX Apr 2024 2.500 put
ANIX Apr 2024 7.500 call
Recap: Anixa Biosciences Q1 Earnings
Anixa Biosciences Inc (ANIX)
ANIX Feb 2024 5.000 call
See More Headlines
Receive ANIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.75 per share


Free Float
Market Cap
$88.36 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Amit Kumar Ph.D. (Age 60)
    CEO, Chairman & Co-Chair of CBAB
    Comp: $1.29M
  • Mr. Michael J. Catelani CPA (Age 57)
    MBA, President, COO, CFO & Corporate Secretary
    Comp: $788.83k
  • Mr. John Roop (Age 74)
    Senior Vice President of Engineering
    Comp: $275k
  • Dr. Pamela D. Garzone Ph.D. (Age 69)
    Chief Development Officer & Chair Breast Cancer Clinical Advisory Board

ANIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Anixa Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anixa Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANIX shares.
View ANIX analyst ratings
or view top-rated stocks.

What is Anixa Biosciences' stock price target for 2024?

1 equities research analysts have issued 1-year price targets for Anixa Biosciences' stock. Their ANIX share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 333.2% from the stock's current price.
View analysts price targets for ANIX
or view top-rated stocks among Wall Street analysts.

How have ANIX shares performed in 2024?

Anixa Biosciences' stock was trading at $3.88 at the beginning of 2024. Since then, ANIX shares have decreased by 28.6% and is now trading at $2.77.
View the best growth stocks for 2024 here

When is Anixa Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024.
View our ANIX earnings forecast

How were Anixa Biosciences' earnings last quarter?

Anixa Biosciences, Inc. (NASDAQ:ANIX) posted its earnings results on Tuesday, March, 12th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01.

What other stocks do shareholders of Anixa Biosciences own?
Who are Anixa Biosciences' major shareholders?

Anixa Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.05%), Simplicity Wealth LLC (0.04%), Staley Capital Advisers Inc. (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amit Kumar, Arnold M Baskies, Lewis H Titterton Jr and Michael Catelani.
View institutional ownership trends

How do I buy shares of Anixa Biosciences?

Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIX) was last updated on 5/21/2024 by Staff

From Our Partners